These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 26197752)

  • 1. [A Case of Fanconi Syndrome Induced by Zoledronic Acid in a Metastatic Colorectal Cancer Patient].
    Okagawa Y; Sato Y; Onuma H; Osuga T; Hayashi T; Sato T; Miyanishi K; Kobune M; Takimoto R; Kato J
    Gan To Kagaku Ryoho; 2015 Jul; 42(7):867-70. PubMed ID: 26197752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of acquired Fanconi syndrome induced by zoledronic acid.
    Yoshinami T; Yagi T; Sakai D; Sugimoto N; Imamura F
    Intern Med; 2011; 50(9):1075-9. PubMed ID: 21532237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome.
    Torimoto K; Okada Y; Arao T; Mori H; Tanaka Y
    Endocr J; 2012; 59(12):1051-6. PubMed ID: 22814143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient.
    Mishra A
    J Postgrad Med; 2008; 54(3):237. PubMed ID: 18626181
    [No Abstract]   [Full Text] [Related]  

  • 5. Zoledronic acid-associated symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): report of baboon syndrome in a woman with recurrent metastatic breast cancer after receiving zoledronic acid.
    Cohen PR
    Dermatol Online J; 2015 Aug; 21(8):. PubMed ID: 26437156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
    Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
    J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?
    Ho JW; Sundar S
    Clin Genitourin Cancer; 2012 Mar; 10(1):50-3. PubMed ID: 22245101
    [No Abstract]   [Full Text] [Related]  

  • 8. Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab.
    Yamasaki M; Yuasa T; Uehara S; Fujii Y; Yamamoto S; Masuda H; Fukui I; Yonese J
    Int J Clin Oncol; 2016 Dec; 21(6):1191-1195. PubMed ID: 27402103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.
    Raje N; Vadhan-Raj S; Willenbacher W; Terpos E; Hungria V; Spencer A; Alexeeva Y; Facon T; Stewart AK; Feng A; Braun A; Balakumaran A; Roodman GD
    Blood Cancer J; 2016 Jan; 6(1):e378. PubMed ID: 26745852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral osteonecrosis associated with the use of zoledronic acid: first case of a patient with advanced pancreatic cancer and bone metastases.
    Smith A; Kressley A; Saif MW
    JOP; 2009 Mar; 10(2):212-4. PubMed ID: 19287122
    [No Abstract]   [Full Text] [Related]  

  • 11. Denosumab and bone metastases. No better than a bisphosphonate.
    Prescrire Int; 2012 Sep; 21(130):204-6. PubMed ID: 23016249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
    Dong M; Feng FY; Zhang Y; Xie GR; Wang YJ; Liu JW; Song ST; Zhou QH; Ren J; Jiao SC; Li J; Wang XW; Chen Q; Wang ZH; Xu N; Feng JF
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):215-20. PubMed ID: 18756940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
    Gulley JL; Wu S; Arlen PM; Dahut WL
    Clin Genitourin Cancer; 2007 Sep; 5(6):403-5. PubMed ID: 17956715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
    Lam MG; Dahmane A; Stevens WH; van Rijk PP; de Klerk JM; Zonnenberg BA
    Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):756-65. PubMed ID: 18157530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid.
    Cappetta A; Spano L; Evangelista L; Zovato S; Opocher G; Pastorelli D
    Anticancer Drugs; 2015 Feb; 26(2):232-5. PubMed ID: 25243456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrolyte abnormalities with zoledronic acid therapy.
    Sorscher SM
    Cancer J; 2002; 8(4):348; author reply 348-9. PubMed ID: 12184414
    [No Abstract]   [Full Text] [Related]  

  • 18. Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study.
    Houston S; Grieve RJ; Hickish T; Percival F; Hamilton E
    J Med Econ; 2010 Mar; 13(1):162-7. PubMed ID: 20136578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibition of RANK ligand to treat bone metastases].
    Body JJ
    Bull Cancer; 2013 Nov; 100(11):1207-13. PubMed ID: 24158618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
    Hu XY; Zou QF; Jin C; Li WD; Chen WS; Ma L
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1343-6. PubMed ID: 20584674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.